Is active acid sphingomyelinase required for the antiproliferative response to rituximab?

Blood

Volumn 117, Issue 13, 2011, Pages 3695-3696

  Sabourdy, Frédérique ^a,b   Selves, Janick ^a,b   Astudillo, Leonardo ^a,b   Laurent, Camille ^a,b   Brousset, Pierre ^a,b   Delisle, Marie Bernadette ^b,c   Therville, Nicole ^b   Andrieu Abadie, Nathalie ^b   Ségui, Bruno ^b   Recher, Christian ^a,b   Levade, Thierry ^a,b  

^a CHU PURPAN   (France)

^b CANCER RESEARCH CENTER OF TOULOUSE   (France)

^c CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE; RITUXIMAB; SPHINGOMYELIN PHOSPHODIESTERASE; VINCRISTINE;

AGED; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; LETTER; MALE; MARGINAL ZONE LYMPHOMA; NIEMANN PICK DISEASE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 79953707904     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-318493     Document Type: Letter

References (10)

1. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008;59:237-250. (Pubitemid 351291630)
2. Michallet AS, Coiffier B. Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev. 2009;23(1):11-23.
3. Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107-114.
4. Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood. 2004;104(4):1166-1173. (Pubitemid 39038039)
5. Smith EL, Schuchman EH. The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J. 2008;22(10):3419-3431.
6. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4(8):604-616. (Pubitemid 39025055)
7. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood. 2006;107(3):1070-1077. (Pubitemid 43156307)
8. Pavlu-Pereira H, Asfaw B, Poupctová H, et al. Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study. J Inherit Metab Dis. 2005;28(2):203-227. (Pubitemid 40723888)
9. Simonaro CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH. The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet. 2002;71(6):1413-1419. (Pubitemid 36015894)
10. de Fost M, Vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006;36(1):53-58. (Pubitemid 43061488)